Josette Fontaine Selected Research

Galactosylceramides (Galactocerebrosides)

1/2017	Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.
11/2016	Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza.
7/2014	Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses.
9/2012	Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide.
2/2012	Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
10/2011	A detrimental role for invariant natural killer T cells in the pathogenesis of experimental dengue virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josette Fontaine Research Topics

Disease

9	Infections 10/2018 - 05/2003
4	Neoplasms (Cancer) 01/2017 - 05/2007
4	Schistosomiasis (Bilharziasis) 02/2006 - 07/2002
3	Melanoma (Melanoma, Malignant) 01/2017 - 01/2008
2	Pneumococcal Infections 11/2016 - 09/2012
2	Superinfection 11/2016 - 06/2013
2	Giardiasis 07/2014 - 01/2004
2	Bacterial Infections (Bacterial Infection) 06/2013 - 09/2012
2	Virus Diseases (Viral Diseases) 03/2012 - 02/2006
2	Neoplasm Metastasis (Metastasis) 02/2009 - 01/2008
1	Bacterial Pneumonia 11/2016
1	Pneumococcal Pneumonia 11/2016
1	Cysts 07/2014
1	Pneumonia (Pneumonitis) 06/2013
1	Communicable Diseases (Infectious Diseases) 06/2013
1	Human Influenza (Influenza) 06/2013
1	Inflammation (Inflammations) 01/2008
1	Experimental Melanoma 01/2008
1	Schistosomiasis mansoni 11/2007
1	Autoimmune Diseases (Autoimmune Disease) 05/2007
1	Wounds and Injuries (Trauma) 01/2004
1	Granuloma 07/2002

Drug/Important Bio-Agent (IBA)

6	Galactosylceramides (Galactocerebrosides)IBA 01/2017 - 10/2011
5	CytokinesIBA 07/2014 - 07/2002
4	LipidsIBA 09/2012 - 01/2008
3	VaccinesIBA 01/2017 - 09/2003
3	AntigensIBA 07/2014 - 01/2004
2	Interferon-gamma (Interferon, gamma)IBA 11/2016 - 07/2014
2	Interleukin-17 (Interleukin 17)IBA 11/2016 - 09/2012
2	Immunoglobulin G (IgG)IBA 07/2014 - 05/2003
2	Interleukin-22 (IL-22)IBA 06/2013 - 03/2012
2	GlycoconjugatesIBA 05/2003 - 07/2002
1	chenodeoxycholate sulfate conjugate (CDCS)IBA 10/2018
1	Interferon Type IIBA 10/2018
1	Interleukin-6 (Interleukin 6)IBA 10/2018
1	AutoantigensIBA 01/2017
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2017
1	MART-1 AntigenIBA 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2016
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2016
1	Antiviral Agents (Antivirals)IBA 11/2016
1	LigandsIBA 07/2014
1	Immunoglobulin E (IgE)IBA 07/2014
1	Proteins (Proteins, Gene)FDA Link 07/2014
1	AntibodiesIBA 07/2014
1	Interleukin-5 (Interleukin 5)IBA 07/2014
1	Interleukin-10 (Interleukin 10)IBA 07/2014
1	Immunoglobulin A (IgA)IBA 07/2014
1	KRN 7000 (KRN7000)IBA 02/2012
1	CD1d AntigensIBA 02/2012
1	CPG-oligonucleotideIBA 02/2009
1	alpha-galactosylceramideIBA 01/2008
1	Prostaglandin D2IBA 01/2008
1	EicosanoidsIBA 01/2008
1	Galectin 3 (LGALS3)IBA 11/2007
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2007
1	GlycolipidsIBA 05/2007
1	Interleukin-4 (Interleukin 4)IBA 02/2006
1	Multifunctional EnzymesIBA 09/2003
1	Glutathione Transferase (Glutathione S-Transferase)IBA 09/2003
1	Polysaccharides (Glycans)IBA 05/2003

Therapy/Procedure

2	Therapeutics 01/2017 - 07/2014
1	Immunotherapy 07/2014
1	Oral Administration 01/2004